ダウンロード数: 141
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
oncotarget.8620.pdf | 5.7 MB | Adobe PDF | 見る/開く |
タイトル: | Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity |
著者: | Shi, Gongping Yoshida, Yoko Yuki, Kanako Nishimura, Tomomi Kawata, Yukiko Kawashima, Masahiro https://orcid.org/0000-0002-4738-8351 (unconfirmed) Iwaisako, Keiko Yoshikawa, Kiyotsugu Kurebayashi, Junichi Toi, Masakazu https://orcid.org/0000-0003-1488-9958 (unconfirmed) Noda, Makoto https://orcid.org/0000-0002-7340-6066 (unconfirmed) |
著者名の別形: | 吉田, 陽子 戸井, 雅和 野田, 亮 |
キーワード: | Breast cancer CpG island DNA methylation Entinostat RECK |
発行日: | 6-Apr-2016 |
出版者: | Impact Journals LLC |
誌名: | Oncotarget |
巻: | 7 |
号: | 50 |
開始ページ: | 82158 |
終了ページ: | 82169 |
抄録: | The membrane-anchored glycoprotein RECK negatively regulates multiple metalloproteinases and is frequently downregulated in tumors. Forced RECK expression in cancer cells results in suppression of tumor angiogenesis, invasion, and metastasis in xenograft models. A previous methylome study on breast cancer tissues detected inverse correlation between RECK CpG methylation (in an intron-1 region) and relapse-free survival. In this study, we focused on another region of the RECK CpG island (a promoter/exon-1 region) and found an inverse correlation between its methylation and RECK-inducibility by an HDAC inhibitor, MS275, among a panel of breast cancer cell lines (n=15). In clinical samples (n=62), RECK intron-1 methylation was prevalent among luminal breast cancers as reported previously (26 of 38 cases; 68%) and particularly enriched in tumors of the ER+PR- subclass (10 of 10 cases) and of higher histological grades (Grade 2 and 3; 28 of 43 cases; P=0.006). In about a half of these cases, promoter/exon-1 methylation was absent, and hence, RECK may be inducible by certain drugs such as MS275. Our results indicate the value of combined use of two RECK methylation markers for predicting prognosis and drugsensitivity of breast cancers. |
著作権等: | All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License. |
URI: | http://hdl.handle.net/2433/218399 |
DOI(出版社版): | 10.18632/oncotarget.8620 |
PubMed ID: | 27058625 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。